The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The pandemic had little impact on mental health symptoms.

2.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

Smoker's Painless Skin Nodules Flag a Fatal Diagnosis

5.

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot